What is GW Pharmaceuticals' stock price and ticker symbol?
What is GW Pharmaceuticals' stock symbol? GW Pharmaceuticals trades on the NASDAQ under the ticker symbol "GWPH." What is GW Pharmaceuticals' stock price today? One share of GWPH stock can currently be purchased for approximately $218.96.
Should you hold GW Pharmaceuticals (gwph) stock?
The consensus among Wall Street research analysts is that investors should "hold" GW Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GWPH, but not buy additional shares or sell existing shares.
How much does GW Pharmaceuticals make a year?
GW Pharmaceuticals has a market capitalization of $6.86 billion and generates $311.33 million in revenue each year. The biopharmaceutical company earns $-9,020,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis. How many employees does GW Pharmaceuticals have? GW Pharmaceuticals employs 1,161 workers across the globe.
What's GW Pharmaceuticals CEO approval rating on Glassdoor?
14 employees have rated GW Pharmaceuticals CEO Justin Gover on Glassdoor.com. Justin Gover has an approval rating of 80% among GW Pharmaceuticals' employees. Who are some of GW Pharmaceuticals' key competitors?
See more
Is GWPH a buy or sell?
The VGM score is based on the trading styles of Growth, VAlue, and Momentum....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy25.08%2Buy18.56%3Hold10.15%4Sell5.79%2 more rows
Is GWPH a good buy?
Based on analyst ratings, GW Pharma's 12-month average price target is $220.00. What is GWPH's upside potential, based on the analysts' average price target? GW Pharma has 0.47% upside potential, based on the analysts' average price target.
How much is GW Pharmaceuticals worth?
As of July 2022 GW Pharmaceuticals has a market cap of $6.81 Billion.
How much is a share of GW Pharmaceuticals?
What is GW Pharmaceuticals' stock price today? One share of GWPH stock can currently be purchased for approximately $218.96.
What happened to GWPH?
Jazz Pharmaceuticals (NASDAQ:JAZZ) has officially closed its $7.2B acquisition of GW Pharmaceuticals plc (NASDAQ:GWPH). GW shareholders gave the thumbs up to the deal last month. With the acquisition, Jazz gains access to GW's cannabinoid portfolio, including Epidiolex, which raked in $510.5M in sales in 2020.
Has GW Pharmaceuticals been sold?
DUBLIN , May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) ("GW"), a leader in the science, development and commercialization of cannabinoid-based prescription medicines.
Who bought GWPH?
Jazz PharmaceuticalsOn Friday, shareholders of GW Pharmaceuticals (GWPH) approved its acquisition by a subsidiary of Jazz Pharmaceuticals (JAZZ 1.65%), both companies announced in a joint press release.
Who owns GW Pharma?
Jazz PharmaceuticalsGW Pharmaceuticals / Parent organizationJazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. Wikipedia
What company owns Epidiolex?
Jazz agreed to pony up $7.2 billion for cannabinoid hotshot GW Pharmaceuticals, whose epilepsy med Epidiolex could be on its way to blockbuster sales. The deal will move Jazz into the epilepsy market, expanding its current offerings beyond sleep disorders and cancer.
Barchart Technical Opinion
The Barchart Technical Opinion rating is a 100% Buy with a Weakening short term outlook on maintaining the current direction.
Business Summary
GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and...
About GW Pharmaceuticals
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas.
GW Pharmaceuticals (NASDAQ:GWPH) Frequently Asked Questions
GW Pharmaceuticals plc (NASDAQ:GWPH) released its quarterly earnings results on Tuesday, November, 3rd. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.63) by $0.27.
About GWPH
GW is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX (cannabidiol) oral solution, is commercialized in the U.S. by its U.S.
Stats
Download the Public app to invest in this stock with any amount of money. Enter your cell phone number below to get started.
Global Wholehealth Partners Corporation Declares Special Common Stock Dividend
San Clemente, CA, Jan.
Goldman Small Cap Research Issues New Research Update on Global WholeHealth Partners Corporation
BALTIMORE, MD / ACCESSWIRE / November 9, 2021 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has released a new company update on Global WholeHealth Partners Corporation (OTC PINK:GWHP). GWHP is a developer and marketer of COVID and other test kits.